{Reference Type}: Journal Article
{Title}: Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.
{Author}: Hirose T;Ito M;Tsuchihashi K;Ozaki Y;Nishio H;Ichihara E;Miura Y;Yano S;Maruyama D;Yoshinami T;Susumu N;Takekuma M;Motohashi T;Baba E;Ochi N;Kubo T;Uchino K;Kimura T;Kamiyama Y;Nakao S;Tamura S;Nishimoto H;Kato Y;Sato A;Takano T;Endo M;
{Journal}: Int J Clin Oncol
{Volume}: 29
{Issue}: 8
{Year}: 2024 Aug 12
{Factor}: 3.85
{DOI}: 10.1007/s10147-024-02569-1
{Abstract}: <B>BACKGROUND: </B>Granulocyte colony-stimulating factor (G-CSF) is an essential supportive agent for chemotherapy-induced severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for non-round cell soft tissue sarcoma (NRC-STS)?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve NRC-STS treatment outcomes?" for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical Oncology.<BR><B>METHODS: </B>A literature search was performed on the primary prophylactic use of G-CSF for NRC-STSs. Two reviewers assessed the extracted papers and analyzed overall survival, incidence of febrile neutropenia, infection-related mortality, quality of life, and pain.<BR><B>RESULTS: </B>Eighty-one and 154 articles were extracted from the literature search for CQs #1 and #2, respectively. After the first and second screening, one and two articles were included in the final evaluation, respectively. Only some studies have addressed these two clinical questions through a literature review.<BR><B>CONCLUSIONS: </B>The clinical questions were converted to future research questions because of insufficient available data. The statements were proposed: "The benefit of primary G-CSF prophylaxis is not clear in NRC-STS" and "The benefit of intensified chemotherapy with primary G-CSF prophylaxis is not clear in NRC-STSs." G-CSF is often administered as primary prophylaxis when chemotherapy with severe myelosuppression is administered. However, its effectiveness and safety are yet to be scientifically proven.